Valeant Pharma (VRX) option implied volatility elevated into Q1 and outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Valeant Pharma (VRX) Reports Q1 Revenues Above Estimates; Boosts FY18 Revenue & EBITDA Outlook
May 8, 2018 7:05 AM EDTValeant Pharma (NYSE: VRX) reported Q1 EPS of ($7.68), versus $0.60 reported last year. Revenue for the quarter came in at $2 billion versus the consensus estimate of $1.95 billion.
Outperformed Expectations in the First Quarter of 2018Revenues of $1.995 BillionGAAP Net Loss of $2.693 BillionGAAP Cash Flow from... More